News summary
[Dizhe Pharmaceuticalbestcryptogames: Shu Wozhebestcryptogames? The latest research results were selected for the 2024 American Society of Clinical Oncology (ASCO) Conference Report] Securities Times e Company Newsbestcryptogames, Digger Pharmaceutical (688192) announced on the evening of May 24 that the company will hold a U.S. clinical oncology conference in Chicago from May 31 to June 4, 2024bestcryptogames...
Newsletter text
[Dizhe Pharmaceutical: Shu Wozhe? The latest research results were selected for the report of the 2024 American Society of Clinical Oncology (ASCO) Conference] Securities Times e Company News, Digger Pharmaceuticals (688192) announced on the evening of May 24 that the company will be held in Chicago from May 31 to June 4, 2024. At the American Society of Clinical Oncology (ASCO) Annual Meeting, it announced its independently developed new Class I lung cancer targeting drug Sulvozer? (Common name: Suvortinib Tablets) Two recent research results on advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions (Exon20ins) mutations. Among them Shu Wozhe? Data from the "WU-KONG1PartB" global registered clinical study on treated EGFRExon20ins mutant NSCLC will be announced for the first time in the form of an oral report at this conference. Preliminary analysis results show that the study has reached its predetermined primary study endpoint. Secondary/posterior line treatment of EGFRExon 20ins mutant NSCLC has demonstrated positive antitumor efficacy and good safety.
